Selective ascorbate toxicity in malignant mesothelioma a redox trojan mechanism

American Journal of Respiratory Cell and Molecular Biology

Volumn 44, Issue 1, 2010, Pages 108-117

  Ranzato, Elia ^a,b   Biffo, Stefano ^a,b   Burlando, Bruno ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Catalase; Hydroxyl radical; Malignant mesothelioma cells; Normal mesothelial cells; NOX4

Indexed keywords

APOCYNIN; ASCORBIC ACID; CATALASE; DEHYDROASCORBIC ACID; DIHYDRHODAMINE 123; FLUORESCENT DYE; HYDROGEN PEROXIDE; NEUTRAL RED; OUABAIN; PHLORETIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; RHODAMINE 123; ROTENONE; SMALL INTERFERING RNA; SODIUM AZIDE; SUPEROXIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL IMMORTALIZATION; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG CYTOTOXICITY; DRUG SELECTIVITY; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; FLUORESCENCE; HUMAN; HUMAN CELL; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PROTEIN EXPRESSION; TUMOR CELL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ASCORBIC ACID; CATALASE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYDROGEN PEROXIDE; INHIBITORY CONCENTRATION 50; MESOTHELIOMA; MICROSCOPY, CONFOCAL; MUTATION; NADPH OXIDASE; NECROSIS; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; OUABAIN; OXIDATION-REDUCTION; OXIDATIVE STRESS; PHLORETIN; RNA INTERFERENCE; SODIUM AZIDE; SUPEROXIDES; SYMPORTERS; TUMOR SUPPRESSOR PROTEIN P53;

STROPHANTHUS GRATUS;

EID: 78650631775     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2009-0340OC     Document Type: Article

References (51)

1. Levine M, Rumsey SC, Daruwala R, Park JB, Wang Y. Criteria and recommendations for vitamin C intake. JAMA 1999;281:1415-1423.
2. McCormick WJ. Cancer: the preconditioning factor in pathogenesis; a new etiologic approach. Arch Pediatr 1954;71:313-322.
3. McCormick WJ. Cancer: a collagen disease, secondary to a nutritional deficiency? Arch Pediatr 1959;76:166-171.
4. Cameron E, Rotman D. Ascorbic acid, cell proliferation, and cancer. Lancet 1972;1:542.
5. Cameron E, Pauling L. Ascorbic acid and the glycosaminoglycans. An orthomolecular approach to cancer and other diseases. Oncology 1973;27:181-192.
6. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 1978;75:4538-4542.
7. Cameron E, Campbell A. Innovation vs. quality control: an "unpublishable" clinical trial of supplemental ascorbate in incurable cancer. Med Hypotheses 1991;36:185-189.
8. Creagan ET, Moertel CG, O'Fallon JR, Schutt AJ, O'Connell MJ, Rubin J, Frytak S. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 1979;301:687-690.
9. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, Ames MM. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 1985;312:137-141.
10. Padayatty SJ, Levine M. Reevaluation of ascorbate in cancer treatment: emerging evidence, open minds and serendipity. J Am Coll Nutr 2000; 19:423-425.
11. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA, Levine M. Vitamin C. Pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 2004;140:533-537.
12. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, Park JB, Lazarev A, Graumlich JF, King J, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 1996; 93:3704-3709.
13. Riordan NH, Riordan HD, Meng X, Li Y, Jackson JA. Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Med Hypotheses 1995;44:207-213.
14. Riordan HD, Casciari JJ, Gonzalez MJ, Riordan NH, Miranda-Massari JR, Taylor P, Jackson JA. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J 2005;24:269-276.
15. Bram S, Froussard P, Guichard M, Jasmin C, Augery Y, Sinoussi-Barre F, Wray W, Vitamin C. Preferential toxicity for malignant melanoma cells. Nature 1980;284:629-631.
16. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E, Levine M. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 2005;102:13604-13609.
17. Carosio R, Zuccari G, Orienti I, Mangraviti S, Montaldo PG. Sodium ascorbate induces apoptosis in neuroblastoma cell lines by interfering with iron uptake. Mol Cancer 2007;6:55.
18. Lin SY, Lai WW, Chou CC, Kuo HM, Li TM, Chung JG, Yang JH. Sodium ascorbate inhibits growth via the induction of cell cycle arrest and apoptosis in human malignant melanoma A375.S2 cells. Melanoma Res 2006;16:509-519.
19. 2+ signal in the ascorbate-induced apoptosis in a human hepatoma cell line. Arch Pharm Res 2004;27: 1245-1252.
20. Hong SW, Jin DH, Hahm ES, Yim SH, Lim JS, Kim KI, Yang Y, Lee SS, Kang JS, Lee WJ, et al. Ascorbate (vitamin C) induces cell death through the apoptosis-inducing factor in human breast cancer cells. Oncol Rep 2007;18:811-815.
21. Kang JS, Cho D, Kim YI, Hahm E, Kim YS, Jin SN, Kim HN, Kim D, Hur D, Park H, et al. Sodium ascorbate (vitamin C) induces apoptosis in melanoma cells via the down-regulation of transferrin receptor dependent iron uptake. J Cell Physiol 2005;204:192-197.
22. Peterkofsky B. Ascorbate requirement for hydroxylation and secretion of procollagen: relationship to inhibition of collagen synthesis in scurvy. Am J Clin Nutr 1991;54:1135-1140.
23. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, Levine M. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 2008;105:11105-11109.
24. Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, Choyke PL, Pooput C, Kirk KL, Buettner GR, et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA 2007;104:8749-8754.
25. Padayatty SJ, Katz A, Wang Y, Eck P, Kwon O, Lee JH, Chen S, Corpe C, Dutta A, Dutta SK, et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr 2003;22:18-35. (Pubitemid 36164454)
26. Tsiouris A, Walesby RK. Malignant pleural mesothelioma: current concepts in treatment. Nat Clin Pract Oncol 2007;4:344-352.
27. Fennell DA, Gaudino G, O'Byrne KJ, Mutti L. van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008;5:136-147.
28. Smythe WR, Hwang HC, Amin KM, Eck SL, Davidson BL, Wilson JM, Kaiser LR, Albelda SM. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res 1994;54:2055-2059.
29. Orecchia S, Schillaci F, Salvio M, Libener R, Betta PG. Aberrant E-cadherin and gamma-catenin expression in malignant mesothelioma and its diagnostic and biological relevance. Lung Cancer 2004;45:S37-S43.
30. Legrand C, Bour JM, Jacob C, Capiaumont J, Martial A, Marc A, Wudtke M, Kretzmer G, Demangel C, Duval D. Lactate dehydrogenase (LDH) activity of the cultured eukaryotic cells as marker of the number of dead cells in the medium. J Biotechnol 1992;25:231-243.
31. Yermolaieva O, Brot N, Weissbach H, Heinemann SH, Hoshi T. Reactive oxygen species and nitric oxide mediate plasticity of neuronal calcium signaling. Proc Natl Acad Sci USA 2000;97:448-453.
32. Greenwald RA. Handbook of methods for oxygen radical research. Boca Raton: CRC Press; 1985.
33. 2 secreted by monocytes and macrophages. Methods Enzymol 1984;105:365-369.
34. Massey V. The microestimation of succinate and the extinction coefficient of cytochrome c. Biochim Biophys Acta 1959;34:255-256.
35. Verrax J, Calderon PB. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med2009.
36. Rumsey SC, Kwon O, Xu GW, Burant CF, Simpson I, Levine M. Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid. J Biol Chem 1997;272:18982-18989.
37. Kato Y, Tsuta K, Seki K, Maeshima AM, Watanabe S, Suzuki K, Asamura H, Tsuchiya R, Matsuno Y. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol 2007;20:215-220.
38. Ibu JO, Short AH. The inhibitory effect of phlorhizin and phloretin on hexose transport in the liver. Scand J Gastroenterol Suppl 1986;124: 75-81.
39. Dixon SJ, Kulaga A, Jaworski EM, Wilson JX. Ascorbate uptake by ROS 17/2.8 osteoblast-like cells: substrate specificity and sensitivity to transport inhibitors. J Bone Miner Res 1991;6:623-629.
40. Wilson JX, Dixon SJ. High-affinity sodium-dependent uptake of ascorbic acid by rat osteoblasts. J Membr Biol 1989;111:83-91.
41. +,K(+)-ATPase. J Biol Chem 1994;269: 19659-19662.
42. Morgulis S, Beber B, Rabkin I. Studies on the effect of temperature on the catalase reaction. I. Effect of different hydrogen peroxide concentrations. J Biol Chem 1926;68:521-533.
43. Heaney ML, Gardner JR, Karasavvas N, Golde DW, Scheinberg DA, Smith EA, O'Connor OA. Vitamin C antagonizes the cytotoxi ceffects of antineoplastic drugs. Cancer Res 2008;68:8031-8038.
44. Wilson J. The physiological role of dehydroascorbic acid. FEBS Lett 2002;527:5-9.
45. Lambeth D. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 2004;4:181-189.
46. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: implications for uncoupling endothelial nitric oxide synthase. Biochem Pharmacol 2005;70:343-354.
47. Riganti C, Gazzano E, Polimeni M, Costamagna C, Bosia A, Ghigo D. Diphenyleneiodonium inhibits the cell redox metabolism and induces oxidative stress. J Biol Chem 2004;279:47726-47731.
48. Young M, Tsao CS. Medium-dependent cytotoxic effect of ascorbate. J Tissue Cult Methods 1992;14:133-138.
49. Halliwell B, Gutteridge JM. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 1984;219:1-14.
50. Chamulitrat W, Schmidt R, Tomakidi P, Stremmel W, Chunglok W, Kawahara T, Rokutan K. Association of GP91PHOX homolog NOX1 with anchorage-independent growth and MAP kinase-activation of transformed human keratinocytes. Oncogene 2003;22:6045-6053.
51. Brar SS, Corbin Z, Kennedy TP, Hemendinger R, Thornton L, Bommarius B, Arnold RS, Whorton AR, Sturrock AB, Huecksteadt TP, et al. NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cells. Am J Physiol Cell Physiol 2003;285: C353-C369.